Try our beta test site
5 studies found for:    Lymphoma OR CLL | BI 836826
Show Display Options
Rank Status Study
1 Recruiting Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Idelalisib;   Drug: BI 836826
2 Recruiting BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Condition: Lymphoma, Non-Hodgkin
Intervention: Drug: BI 836826
3 Recruiting To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
Condition: Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: BI 836826;   Drug: GemOx;   Drug: Rituximab
4 Active, not recruiting BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Drug: BI 836826
5 Recruiting Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: BI 836826;   Drug: Ibrutinib

Study has passed its completion date and status has not been verified in more than two years.